Loading
A phase 3 trial of atezolizumab in lung cancer, run by National Cancer Institute (NCI), now recruiting.
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial is a phase 3, randomised interventional study registered as NCT07388524 by National Cancer Institute (NCI), with a registry enrolment figure of 336 participants, started 2027-03-02 and due to reach its primary completion in 2032-09-30. Interventions recorded: Atezolizumab; Atezolizumab and Recombinant Human Hyaluronidase; Biospecimen Collection; Computed Tomography; Patient Observation. Conditions listed: Lung Non-Small Cell Carcinoma. Primary outcome: Disease-free survival. Lung eligibility wording from the registry: "* Pathologically stage IA3 or IB NSCLC per American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 9th edition". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.